Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

G Livingston, J Huntley, KY Liu, SG Costafreda… - The Lancet, 2024 - thelancet.com
Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

GB Frisoni, D Altomare, DR Thal, F Ribaldi… - Nature Reviews …, 2022 - nature.com
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

R Ossenkoppele, A Pichet Binette, C Groot, R Smith… - Nature medicine, 2022 - nature.com
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

S Salloway, M Farlow, E McDade, DB Clifford… - Nature medicine, 2021 - nature.com
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders

S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg… - Jama, 2020 - jamanetwork.com
Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease

NR Barthélemy, Y Li, N Joseph-Mathurin, BA Gordon… - Nature medicine, 2020 - nature.com
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ …

M Suárez‐Calvet, TK Karikari, NJ Ashton… - EMBO molecular …, 2020 - embopress.org
In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …

The human connectome in Alzheimer disease—relationship to biomarkers and genetics

M Yu, O Sporns, AJ Saykin - Nature Reviews Neurology, 2021 - nature.com
The pathology of Alzheimer disease (AD) damages structural and functional brain networks,
resulting in cognitive impairment. The results of recent connectomics studies have now …

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

R van der Kant, LSB Goldstein… - Nature Reviews …, 2020 - nature.com
The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …